Next steps in clinical trial redesign.
Joanne
J
Nicholas
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics / Q000379:methods* / Q000639:trends*; D015507:Drugs, Investigational / Q000627:therapeutic use; D028744:Ethics Committees, Research; D005060:Europe; D005104:Expert Testimony; D006801:Humans; D007258:Informed Consent / Q000592:standards; D008495:Medical Oncology; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D054547:National Cancer Institute (U.S.); D018579:Patient Selection; D057285:Precision Medicine / Q000592:standards / Q000639:trends; D012107:Research Design / Q000639:trends*; D012109:Research Support as Topic; D012955:Societies, Medical; D057170:Translational Research, Biomedical / Q000379:methods / Q000592:standards / Q000639:trends; D014481:United States
D000970:Antineoplastic Agents; D015507:Drugs, Investigational